Windward Capital Management Co. CA Sells 539 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Windward Capital Management Co. CA has reduced its stake in Thermo Fisher Scientific by 1.5%, selling 539 shares and holding a total of 34,621 shares, which are now worth approximately $17.2 million.
• Major institutional investors have increased their positions in Thermo Fisher Scientific, including Mondrian Investment Partners, which raised its stake by 146.1%, now owning 214,506 shares valued at $106.7 million.
• Thermo Fisher Scientific recently declared a quarterly dividend of $0.43 per share, with a payout ratio of 9.95%, and a current dividend yield of 0.4%.

Windward Capital Management Co. CA lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,621 shares of the medical research company's stock after selling 539 shares during the period. Thermo Fisher Scientific accounts for 1.5% of Windward Capital Management Co. CA's holdings, making the stock its 24th largest holding. Windward Capital Management Co. CA's holdings in Thermo Fisher Scientific were worth $17,228,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its holdings in shares of Thermo Fisher Scientific by 1.3% during the first quarter. Steward Partners Investment Advisory LLC now owns 33,163 shares of the medical research company's stock worth $16,502,000 after purchasing an additional 414 shares during the period. Forvis Mazars Wealth Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific by 6.3% during the first quarter. Forvis Mazars Wealth Advisors LLC now owns 7,624 shares of the medical research company's stock worth $3,794,000 after purchasing an additional 452 shares during the period. Tocqueville Asset Management L.P. lifted its holdings in shares of Thermo Fisher Scientific by 6.3% during the first quarter. Tocqueville Asset Management L.P. now owns 80,473 shares of the medical research company's stock worth $40,043,000 after purchasing an additional 4,790 shares during the period. Gen Wealth Partners Inc lifted its holdings in shares of Thermo Fisher Scientific by 20.3% during the first quarter. Gen Wealth Partners Inc now owns 1,593 shares of the medical research company's stock worth $792,000 after purchasing an additional 269 shares during the period. Finally, LWM Advisory Services LLC lifted its holdings in shares of Thermo Fisher Scientific by 36.1% during the first quarter. LWM Advisory Services LLC now owns 1,010 shares of the medical research company's stock worth $496,000 after purchasing an additional 268 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 2.3%

Thermo Fisher Scientific stock traded down $11.3820 during midday trading on Thursday, hitting $483.4280. 1,353,599 shares of the stock were exchanged, compared to its average volume of 2,488,745. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88. The stock has a market capitalization of $182.55 billion, a price-to-earnings ratio of 27.96, a price-to-earnings-growth ratio of 2.66 and a beta of 0.74. The business's 50-day moving average price is $439.69 and its 200-day moving average price is $458.78. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total value of $3,635,600.00. Following the transaction, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,340,824.30. This represents a 6.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TMO shares. Royal Bank Of Canada dropped their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research note on Tuesday, April 29th. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Finally, Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.